Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Liabilities (2016 - 2025)

Coherus Oncology's Total Liabilities history spans 13 years, with the latest figure at $197.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 66.01% year-over-year to $197.3 million; the TTM value through Dec 2025 reached $197.3 million, down 66.01%, while the annual FY2025 figure was $197.3 million, 66.01% down from the prior year.
  • Total Liabilities for Q4 2025 was $197.3 million at Coherus Oncology, down from $428.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $845.4 million in Q1 2024 and bottomed at $197.3 million in Q4 2025.
  • The 5-year median for Total Liabilities is $588.1 million (2021), against an average of $591.0 million.
  • The largest annual shift saw Total Liabilities skyrocketed 82.9% in 2021 before it crashed 66.01% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $581.6 million in 2021, then grew by 6.3% to $618.3 million in 2022, then soared by 33.12% to $823.0 million in 2023, then dropped by 29.47% to $580.5 million in 2024, then plummeted by 66.01% to $197.3 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Total Liabilities are $197.3 million (Q4 2025), $428.7 million (Q3 2025), and $319.6 million (Q2 2025).